Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma

Advanced stage neuroblastoma is an aggressive disease with limited treatment options for patients with drug-resistant tumors. Targeted delivery of chemotherapy for pediatric cancers offers promise to improve treatment efficacy and reduce toxicity associated with systemic chemotherapy. The EnGeneIC D...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer therapeutics Vol. 17; no. 5; pp. 1012 - 1023
Main Authors Sagnella, Sharon M, Trieu, Jennifer, Brahmbhatt, Himanshu, MacDiarmid, Jennifer A, MacMillan, Alex, Whan, Renee M, Fife, Christopher M, McCarroll, Joshua A, Gifford, Andrew J, Ziegler, David S, Kavallaris, Maria
Format Journal Article
LanguageEnglish
Published United States American Association for Cancer Research Inc 01.05.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Advanced stage neuroblastoma is an aggressive disease with limited treatment options for patients with drug-resistant tumors. Targeted delivery of chemotherapy for pediatric cancers offers promise to improve treatment efficacy and reduce toxicity associated with systemic chemotherapy. The EnGeneIC Dream Vector (EDV ) is a nanocell, which can package chemotherapeutic drugs and target tumors via attachment of bispecific proteins to the surface of the nanocell. Phase I trials in adults with refractory tumors have shown an acceptable safety profile. Herein we investigated the activity of EGFR-targeted and doxorubicin-loaded EDV ( EDV ) for the treatment of neuroblastoma. Two independent neuroblastoma cell lines with variable expression of EGFR protein [SK-N-BE(2), high; SH-SY-5Y, low] were used. EDV induced apoptosis in these cells compared to control, doxorubicin, or non-doxorubicin loaded EDV In three-dimensional tumor spheroids, imaging and fluorescence life-time microscopy revealed that EDV had a marked enhancement of doxorubicin penetration compared to doxorubicin alone, and improved penetration compared to non-EGFR-targeted EDV , with enhanced spheroid penetration leading to increased apoptosis. In two independent orthotopic human neuroblastoma xenograft models, short-term studies (28 days) of tumor-bearing mice led to a significant decrease in tumor size in EDV -treated animals compared to control, doxorubicin, or non-EGFR EDV There was increased TUNEL staining of tumors at day 28 compared to control, doxorubicin, or non-EGFR EDV Moreover, overall survival was increased in neuroblastoma mice treated with EDV ( < 0007) compared to control. Drug-loaded bispecific-antibody targeted EDVs offer a highly promising approach for the treatment of aggressive pediatric malignancies such as neuroblastoma. .
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1535-7163
1538-8514
DOI:10.1158/1535-7163.MCT-17-0738